Healthcare

For the year ended 30 June 2026, CSL reportedRevenueof US$15.797 billion, representing growth of 2 per cent on a reported basis but a decline of 1 per cent in constant currency.

For the year ended 30 June 2026, Medibank reported statutory net profit after tax of $638.7 million, an increase of 27.5 per cent from the prior year.

Cash reserves fell to $800,145 from $5,757,474, and the group moved from netAssetsof $1,974,514 to net liabilities of $7,722,773. The report states that the accounts are still being audited and that directors expect an unmodified opinion with a material uncertainty related toGoing Concernby the …

The year was dominated by two clinical readouts in June 2026. The Phase 2 trial of CYP-001 in acute graft versus host disease and the Phase 3 SCUlpTOR trial of CYP-004 in knee osteoarthritis both failed to show a benefit over control. On 6 …

Phoslock Environmental Technologies Ltd (ASX:PET) is an Australian water treatment company that develops and commercialises lanthanum-modified bentonite clay products designed to bind phosphorus in water bodies, preventing or mitigating algal blooms and improving water quality. The company's principal product is Phoslock, a proprietary 5% …

Osteopore Limited (ASX:OSX) is a regenerative medicine company specialising in the development and commercialisation of 3D-printed biomimetic and bioresorbable implants for bone reconstruction. The company's flagship product addresses medial opening wedge high tibial osteotomy procedures, and its broader orthopaedic product range includes scaffolds for …

Argent BioPharma Ltd (ASX:RGT, formerly MGC Pharmaceuticals Limited) is an ASX-listed clinical-stage biopharmaceutical company headquartered in Subiaco, Western Australia, with research andManufacturingfacilities in Slovenia and Malta. The company's core pipeline includes CimetrA (anti-inflammatory and anti-infective, targeting acute lung injury and ARDS), CannEpil (drug-resistant epilepsy), …